In a prospective and observational study, Husain-Syed reported that [TIMP-2] • [IGFBP7] had no effect on predicting AKI in patients with COVID-19, but higher [TIMP-2] • [IGFBP7] levels were associated with adverse clinical outcomes, including the severity of AKI, requirement of RRT, and death [92]. Here, IGFBP7 is linked to acute kidney injury.